Viatris (VTRS)
Markets established brands, complex generics, and newer innovative medicines worldwide.
Something off on this page? Send us feedback.
Markets established brands, generic and complex generic medicines, and a developing portfolio of innovative drugs through four geographic businesses. Revenue spans developed and emerging markets, while approvals, regulated pricing, manufacturing quality, and reliable supply shape results.
Markets branded medicines, generic and complex generic drugs, and a developing set of patent-protected products across cardiovascular, infectious disease, respiratory, central nervous system, and other therapeutic areas. Established brands such as Lipitor, Norvasc, Lyrica, Viagra, EpiPen, and Creon sit alongside higher-volume generics and complex products including inhaled and injectable therapies. Sales are managed through Developed Markets, Greater China, JANZ, and Emerging Markets.
Uses an integrated research, regulatory, manufacturing, supply-chain, and commercial platform to launch and distribute medicines in more than 165 countries and territories. Portfolio simplification divested the owned biosimilars platform, most consumer health, women's health, and Indian active-ingredient operations, while investment shifted toward limited-competition generics, value-added medicines, and innovative brands. Performance depends on drug approvals, regulated pricing and reimbursement, patent and exclusivity cycles, manufacturing compliance, and reliable global supply.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Target | Target: — | Target: $20 |
| Sep 8, 2026 | Argus Research | Reiterate | Rating: —Target: $15 | Target: $20 |
| May 19, 2026 | Barclays | Reiterate | Rating: —Target: $15 | Target: $22 |
| May 8, 2026 | Truist Financial | Target | Target: $16 | Target: $20 |
| Feb 9, 2026 | UBS | Target | Target: $12 | Target: $18 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.51B · Total debt $13.63B · Total assets $35.04B · Shareholders' equity $14.26B
- Revenue
- $3.76B
- Operating income
- $6.3M
- Net income
- −$118.8M
HistoryDividendAnnual yield
| Institutions | 92.22% | 1.06B shares | |
|---|---|---|---|
| 1,062 holders · as of Jun 30, 2026 | |||
| Insiders | 0.18% | 2.09M shares | |
| 19 holders · as of Aug 18, 2026 | |||
| Other | 7.60% | 87.22M shares | |
| remainder | |||
1.15B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 8.42% | 96.66M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.49% | 86.02M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.62% | 76.05M | as of Jun 30, 2026 |
Davis Selected AdvisersInstitution | 6.55% | 75.23M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 5.94% | 68.21M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 25, 2026 | Paul Campbell | officer: See Remarks | −50,076 | $16.17 |
| Mar 23, 2026 | Paul Campbell | officer: See Remarks | −21,350 | $13.28 |
| Aug 27, 2025 | David S. Simmons | director | +286 | $10.42 |
| Nov 3, 2025 | David S. Simmons | director | +213 | $10.43 |
- Teva (ADR)
Broad global peer in generics, biosimilars, and selected brands
- Organon
Established-brand and biosimilar peer with mature-product exposure
- Dr. Reddy's Laboratories (ADR)
Global generics and branded-generics rival with U.S. scale
- Amneal Pharmaceuticals
U.S. generics peer across retail, injectables, and biosimilars
- Bausch + Lomb
Ophthalmology peer across dry eye and eye-care pharmaceuticals
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Viatris | $17.19 | +0.50% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| Teva (ADR) | $39.65 | −1.02% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Organon | $13.71 | +0.22% | $3.59B | 17.8 | 3.9 | 0.6 | +0.5% |
| Dr. Reddy's Laboratories (ADR) | $12.61 | +1.65% | $10.33B | 29.8 | 33.6 | 3.0 | −15.5% |
| Amneal Pharmaceuticals | $19.52 | −3.19% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| Bausch + Lomb | $17.32 | +3.10% | $6.00B | — | 17.3 | 1.1 | +9.1% |
| Median | 35.6 | 17.3 | 2.1 | +0.5% |